In vitro antifungal activity of sertaconazole

Area of Science:

• Mycology
• Pharmacology
• Antimicrobial Agents

Background:

• Fungal infections pose significant health challenges, necessitating the development of effective antifungal agents.
• Azole antifungals are a cornerstone in treating various mycoses.
• Comparing the efficacy of established and novel antifungal compounds is crucial for clinical application.

Purpose of the Study:

• To evaluate and compare the in vitro antifungal activity of sertaconazole against miconazole.
• To determine the minimum inhibitory concentrations (MICs) and fungicidal activity of sertaconazole against a range of fungal pathogens.

Main Methods:

• In vitro susceptibility testing was performed using standardized microbiological assays.
• Minimum Inhibitory Concentrations (MICs) were determined for various fungal species, including Candida albicans, Candida non-albicans, Torulopsis, Trichosporon, dermatophytes, and filamentous fungi.
• Fungicidal activity against Candida albicans was assessed.

Main Results:

• Sertaconazole exhibited high sensitivity against Candida albicans (MIC = 0.21 µg/ml) and other yeasts like Torulopsis and Trichosporon (MIC = 0.09 µg/ml).
• Partial inhibition of dermatophytes was observed, with 50% inhibition ranging from 0.36 to 12.56 µg/ml.
• Sertaconazole demonstrated lower MICs than miconazole against filamentous opportunistic fungi and showed remarkable fungicidal activity against all Candida albicans strains tested.

Conclusions:

• Sertaconazole possesses broad-spectrum in vitro antifungal activity, with notable efficacy against yeasts and Candida albicans.
• Its fungicidal properties against Candida albicans suggest potential therapeutic value.
• Sertaconazole represents a promising antifungal agent, potentially offering advantages over miconazole in specific applications.